SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets, Data Centers, and Treasury and Corporate. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The Treasury and Corporate segment includes the company’s proprietary trading and mining activities, as well as the company’s principal investments and related gains and losses. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

Galaxy Digital is facing intense scrutiny and bearish sentiment from investors concerned about a lack of clear communication regarding the company's Helios data center progress and perceived mismanagement. Despite interest from institutional research desks, the stock is currently struggling with high volatility and underperformance, leading many in the community to express frustration over the silence from leadership during recent market fluctuations.

VisionWave Holdings, Inc. engages in the forefront of revolutionizing defense capabilities by integrating advanced artificial intelligence (AI) and autonomous solutions across air, ground, and sea domains. The company was founded on March 20, 2024 and is headquartered in Wilmington, DE.

VisionWave Holdings Inc.

VisionWave Holdings, Inc.

VisionWave Holdings is gaining momentum as investors react to a newly granted patent for its real-time RF motion detection technology and ongoing strategic expansion into defense-focused AI and autonomous systems. The community is actively discussing the potential for a parabolic breakout, citing the stock's low float and recent high-profile institutional interest as catalysts for a potential squeeze.

Penguin Solutions, Inc. engages in designing, building, and managing enterprise solutions. It operates through the following segments: Advanced Computing, Integrated Memory, and Optimized LED. The Advanced Computing segment offers platform solutions and services for artificial intelligence, high-performance computing, machine learning, advanced modeling, and the internet of things. The Integrated Memory refers to integrated memory solutions through the design and development. The Optimized LED segment comprises a broad portfolio of application-optimized LEDs. The company was founded in 1988 and is headquartered in Fremont, CA.

Penguin Solutions Inc.

Penguin Solutions is drawing significant investor interest as the community weighs strong financial performance, including consistent earnings beats and strategic partnerships with industry giants like NVIDIA and Meta, against volatility surrounding its future growth guidance. Traders are actively debating the company's valuation as a "deep-value" AI infrastructure play, while monitoring technical levels for potential breakouts fueled by its expanding AI/HPC pipeline.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience is generating significant buzz as traders monitor its potential for extreme volatility, often drawing historical comparisons to past low-float runners that experienced parabolic price swings. The community remains deeply divided, with some betting on a short squeeze fueled by tight share structures and high borrow fees, while others caution that the asset's price action resembles a speculative pump-and-dump scenario.

Tema ETF Trust - Tema Space Innovators ETF

The Tema Space Innovators ETF (NASA) is gaining traction as a new, actively managed vehicle providing retail investors with exposure to the space economy, specifically through its allocation to SpaceX ahead of a highly anticipated IPO. Community members are actively debating the fund's growth potential and AUM size compared to similar products, with many using the ticker to gain exposure to space-sector tailwinds and upcoming lunar mission catalysts.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is surging as investors pivot toward the space sector following the company's new NASA contract and rising anticipation for the upcoming Artemis II mission. The community is actively debating the stock's momentum, with intense discussions focused on potential short squeezes, institutional accumulation, and the broader implications of a possible SpaceX IPO.

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

ORIC Pharmaceuticals Inc

ORIC Pharmaceuticals is surging following the announcement of a clinical development collaboration with Pfizer for its multiple myeloma candidate, alongside a private placement financing deal. The community is actively debating the stock's massive upside potential driven by this institutional endorsement and high short interest, while some traders caution against volatility as they watch for sustained volume to fuel a potential squeeze.

SharonAI Holdings, Inc. engages in providing high-performance computing (HPC), artificial intelligence (AI), and cloud GPU compute infrastructure technologies. The company was founded on December 30, 2024 and is headquartered in New York, NY.

SharonAI Holdings Inc. - Ordinary Shares - Class A

SharonAI is seeing intense market interest following the announcement of a major multi-year AI infrastructure contract, with the community actively speculating on its potential for a significant short squeeze due to the stock's low float. Traders are closely monitoring the price action and volume levels, debating whether this partnership validates the company's long-term growth or if the current market dynamics suggest further volatility ahead.

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

Alto Neuroscience Inc.

Alto Neuroscience is seeing significant market activity and intense community discussion following the FDA's granting of Fast Track designation to ALTO-101 for the treatment of cognitive impairment associated with schizophrenia. Investors are closely monitoring upcoming clinical trial readouts while debating the company's long-term potential, with many highlighting its strong cash runway and precision psychiatry pipeline as key drivers for long-term growth.

Lamb Weston Holdings, Inc. engages in the production, distribution, and marketing of value-added frozen potato products. It operates through the North America and International segments. The North America segment includes frozen potato products sold in the United States, Canada, and Mexico to quick service and full-service restaurants and chains, foodservice distributors, non-commercial channels, and retailers. International segment primarily includes frozen potato products sold outside of North America. The company was founded in 1950 and is headquartered in Eagle, ID.

Lamb Weston Holdings Inc

Lamb Weston is trending as investors weigh activist investor Starboard Value's push for operational reforms against the company's recent earnings results, which featured downward guidance and notable margin pressure. The community is actively debating the stock's potential as a buyout target versus concerns that a lack of competitive moat could lead to market share loss.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biogen Secures FDA Nod for Higher Dose of SMA Drug Spinraza

BIIB gains after the FDA clears higher-dose Spinraza, with data showing improved motor function and potential to counter rising SMA competition.

Assenagon Asset Management S.A. Cuts Stake in Ionis Pharmaceuticals, Inc. $IONS

Assenagon Asset Management S.A. cut its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 90.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 29,316 shar...

Why Is Ionis Pharmaceuticals (IONS) Down 7.9% Since Last Earnings Report?

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ionis Pharmaceuticals Repriced Drug Ahead Of Key FDA Decision Signals Push Into Larger Market

Ionis Pharmaceuticals cuts Tryngolza price ahead of sHTG decision, with analysts seeing stronger sales potential and competitive positioning.read more...

Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $106.00 at Barclays

Barclays increased their price target on shares of Ionis Pharmaceuticals from $95.00 to $106.00 and gave the stock an "overweight" rating in a report on Thursday...

What is HC Wainwright's Estimate for IONS FY2027 Earnings?

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) - Research analysts at HC Wainwright issued their FY2027 EPS estimates for Ionis Pharmaceuticals in a note issued to investors on Wednesday, March 25th. HC Wainwright analyst M. Kapoor forecasts that the company will post earnings of ($0.35) pe...

Needham & Company LLC Issues Positive Forecast for Ionis Pharmaceuticals (NASDAQ:IONS) Stock Price

Needham & Company LLC raised their price objective on shares of Ionis Pharmaceuticals from $103.00 to $105.00 and gave the company a "buy" rating in a research report on Wednesday...

Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $120.00 at HC Wainwright

HC Wainwright increased their price objective on Ionis Pharmaceuticals from $110.00 to $120.00 and gave the company a "buy" rating in a report on Wednesday...

FDA Grants Priority Tag to Ionis' NDA for Alexander Disease Drug

IONS wins FDA priority review for zilganersen in rare Alexander disease, with a Sept. 22, 2026, decision date backed by strong phase III data.

Insider Selling: Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells 5,812 Shares of Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) EVP Eugene Schneider sold 5,812 shares of Ionis Pharmaceuticals stock in a transaction on Thursday, March 19th. The stock was sold at an average price of $70.97, for a total value of $412,477.64. Following the sale, the executive vice...

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.

Ionis Pharmaceuticals Inc

Thematic ETFs

Prediction Markets

OpenClaw & Agentic-Directed Trading

Tokenization

Recognizing the tool or mechanism that redefined how we trade. From prediction markets to next-gen tech, this award honors the innovation that pushed the boundaries of access and efficiency in modern finance.

Current Price	$75.13
Prev Close	$75.09
Open	$75.70
Dividend Yield	0.00%
50-Day Moving Average	$78.72
Beta	0.71
Avg. Volume	2.15M
PE Ratio	-30.44

52-Week High	$86.74
52-Week Low	$23.95
Market Capitalization	$12.4B
EPS (Annual)	-$2.38
Price to Book	25.07
Revenue Per Employee	$673,117.69

IONS
Ionis Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IONS News

IONSIonis Pharmaceuticals Inc